Novel EUS-guided microwave ablation of an unresectable pancreatic neuroendocrine tumor
Carlos Robles‐Medranda, Martha Arevalo-Mora, Roberto Oleas, Juan Alcívar-Vásquez, Raquel Del Valle
Abstract
Pancreatic neuroendocrine tumors have an incidence of ≤1 case per 100,000 individuals, accounting for up to 2% of all pancreatic neoplasms in the United States. The 5-year overall survival rate ranges from 37.6% to 50%.1 Curative surgical interventions are not feasible for most patients because most cases are detected in advanced unresectable stages, mainly in elderly patients with several comorbidities.2 Therefore, developing safe and effective alternatives for patients unfit for surgery is imperative for clinical practice.
Topics & Concepts
MedicineMicrowave ablationNeuroendocrine tumorsPancreatic neuroendocrine tumorAblationRadiologyGeneral surgeryInternal medicineNeuroendocrine Tumor Research AdvancesParticle accelerators and beam dynamicsParticle Accelerators and Free-Electron Lasers